Table 3.
Platelet Analysis for Patients Treated for More Than 4 Weeks
| Variable | Low-dose group | High-dose group | Placebo | PA | PHP | PLP |
|---|---|---|---|---|---|---|
| No. of patients | 55 | 48 | 55 | |||
| Age (years) | 54.7±12.1 | 55.4±11.0 | 56.7±9.6 | 0.62 | 0.52 | 0.34 |
| Gender, male (%) | 29 (%) | 24 (%) | 31 (%) | 0.81 | 0.78 | 0.70 |
| BMI (kg/m2) | 23.3±3.5 | 23.0±3.1 | 24.5±3.2 | 0.04 | 0.02 | 0.05 |
| Platelet counts (×103/μL) | ||||||
| Week 0 | 150.4±54.1 | 138.7±71.1 | 133.9±50.9 | 0.32 | 0.69 | 0.10 |
| Week 4 | 185.4±56.7 | 165.1±69.5 | 158.8±53.7 | 0.06 | 0.61 | 0.01 |
| Week 12 | 177.1±49.1 | 160.9±67.4 | 151.9±51.5 | 0.07 | 0.47 | 0.01 |
| Week 24 – treatment stopped | 195.7±48.7 | 165.2±59.6 | 162.8±58.3 | 0.007 | 0.85 | 0.004 |
| Week 36 | 194.5±52.0 | 171.8±60.3 | 163.8±56.3 | 0.03 | 0.53 | 0.007 |
| Week 48 | 203.4±52.7 | 167.0±53.1 | 167.6±59.0 | 0.002 | 0.96 | 0.003 |